WO1996038541A1 - Survie et regeneration de longue duree de neurones du systeme nerveux central - Google Patents

Survie et regeneration de longue duree de neurones du systeme nerveux central Download PDF

Info

Publication number
WO1996038541A1
WO1996038541A1 PCT/US1996/008079 US9608079W WO9638541A1 WO 1996038541 A1 WO1996038541 A1 WO 1996038541A1 US 9608079 W US9608079 W US 9608079W WO 9638541 A1 WO9638541 A1 WO 9638541A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
growth factor
survival
culture
camp
Prior art date
Application number
PCT/US1996/008079
Other languages
English (en)
Inventor
Barbara A. Barres
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Priority to AU60267/96A priority Critical patent/AU6026796A/en
Publication of WO1996038541A1 publication Critical patent/WO1996038541A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system

Definitions

  • the present invention relates to neurotrophic factors and culture conditions that promote survival and regeneration of central nervous system (CNS) neurons, particularly survival under defined (e.g., serum-free) conditions.
  • CNS central nervous system
  • the survival of neurons in the mammalian brain throughout the lifetime of the animal depends on continuous signalling by neurotrophic peptide factors. Both developing and adult central nervous system (CNS) and peripheral nervous system (PNS) neurons undergo apoptosis (programmed cell death) when deprived of survival signals. Survival signals are generally peptide trophic factors that are provided by neighboring cell types. The factors act by inhibiting a constitutively active program of cell death (Raff, 1992; Raff, et al., 1993).
  • Survival control mechanisms are thought to help to match the number of pre- and postsynaptic target neurons. For instance, neurons are generally overproduced during normal development (often by at least a factor of two) and a competition between the presynaptic neurons for a limiting amount of target-derived trophic factors determines which cells live and which cells die (Cowan, et al., 1984; Purves, 1988). The same survival signals that control cell survival also control survival and growth of neuronal processes and nerve terminals (Cowan, et al., 1984; Campenot, 1994).
  • PNS neurons including ventral horn motor neurons, sympathetic neurons, and dorsal root ganglion sensory neurons, may be purified and the signaling processes that promote their survival studied (e.g., see review by Barde, et al., 1989).
  • the mechanisms that normally control the survival of PNS neurons have been elucidated by studying the properties of purified neurons in culture. This work has demonstrated that the survival of highly purified PNS neurons, including sensory, sympathetic, ciliary and motor neurons, can be promoted by single peptide trophic factors under serum-free conditions (e.g., see review by Barde, et al., 1989).
  • the present invention includes an in vitro culture of central nervous system (CNS) neuronal cells.
  • the culture is characterized by (i) an absence of feeder cells or medium conditioned by feeder cells, (ii) substantially serum-free culture medium, and (iii) short-term viability.
  • Short-term viability is defined by (i) at least 30% cell survival after 3 days of culture, and (ii) maintenance of cell characteristics, as evidenced by the presence of a measurable cell-specific marker in the surviving cells after 3 days.
  • the culture contains postnatal CNS neuronal cells and is further characterized by long-term viability, as defined by (i) at least 30% cell survival after 7 days of culture, and (ii) maintenance of cell characteristics, as evidenced by the presence of a measurable cell-specific marker in the surviving cells after 7 days.
  • the culture is further characterized by very long-term viability, as defined by at least 30% cell survival after 28 days of culture.
  • the CNS neuronal cells in the above-described cultures may be prenatal neuronal cells or postnatal neuronal cells.
  • the cells may be glutamatergic projection neurons, such as cortical projection neurons or retinal ganglion cells.
  • the cell-specific marker may be, for example, MAP-2 or tau.
  • the invention includes a method of growing an in vitro culture of central nervous system (CNS) neuronal cells.
  • the method includes incubating the cells in a medium which (i) is substantially free of feeder cells or medium conditioned by feeder cells, (ii) is substantially serum-free, and (iii) contains a first growth factor effective to increase survival time of the cells, and growing the cells under conditions effective to stimulate cAMP-dependent protein kinases in the cells.
  • the first growth factor employed in the above method may be, for example, insulin, brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), neurotrophin-4/5 (NT-4/5), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), basic fibroblast growth factor (bFGF), or transforming growth factor-alpha (TGF- ⁇ ).
  • BDNF brain-derived neurotrophic factor
  • IGF-1 insulin-like growth factor 1
  • IGF-2 insulin-like growth factor 2
  • NT-4/5 neurotrophin-4/5
  • CNTF ciliary neurotrophic factor
  • LIF leukemia inhibitory factor
  • IL-6 interleukin-6
  • bFGF basic fibroblast growth factor
  • TGF- ⁇ transforming growth factor-alpha
  • the conditions effective to stimulate a cAMP-dependent protein kinase include pharmacological manipulations, such as exposing the cells to forskolin or membrane- permeable analogs of cAMP, such as chlorophenylthio-cAMP (CPTcAMP), Sp-cAMP or 8- bromo cAMP.
  • the conditions effective to stimulate cAMP-dependent protein kinases may include depolarizing the cells in the presence of about 200 ⁇ M to 10 mM (i.e., physiological extracellular levels) extracellular calcium. Such depolarizing may be accomplished, for example, by exposing the cells to elevated levels of extracellular potassium, exposing the cells to a glutamate receptor agonist, or by electrically stimulating the cells, for example, with an implantable stimulating electrode.
  • the cells suitable for culturing by the above method include glutamatergic projection neurons, such as retinal ganglion cells and cortical projection neurons.
  • the medium employed in the above method further includes a second growth factor, which is effective to further increase the survival time of the cells.
  • the medium contains, in addition to the first and second growth factors, a third growth factor effective to further increase the survival time of the cells.
  • the first growth factor may be an insulin-like growth factor (e.g., insulin, IGF-1 or IGF-2)
  • the second growth factor may be a neurotrophin (e.g., BDNF or NT-4/5)
  • the third growth factor may be a CNTF-like cytokine (e.g., CNTF, LIF or IL-6).
  • first growth factor may be a neurotrophin
  • second growth factor may be a CNTF-like cytokine, and so-on.
  • the invention includes a method of extending the survival time of an in vitro culture of central nervous system (CNS) neuronal cells.
  • the method includes maintaining the cells (i) in the presence of a first growth factor, and (ii) under conditions effective to stimulate cAMP-dependent protein kinases in said cells.
  • the survival time of cells maintained as stated in this method is longer than the survival time of cells not maintained in this manner.
  • the culture is a substantially serum-free culture.
  • the culture does not contain feeder cells or medium conditioned by feeder cells.
  • the growth factor used with the above-described aspect of the invention may be, for example, insulin, BDNF, IGF-1, IGF-2, NT-4/5, CNTF, LIF, IL-6, bFGF, or TGF- ⁇ , and the conditions effective to stimulate a cAMP-dependent protein kinase may include any of those recited above for other aspects of the invention.
  • the cells amenable for use with the method also include those cell types recited above.
  • the method includes adding a second growth factor to the culture. In a related embodiment, the method includes adding a third growth factor to the culture.
  • the first, second and third growth factors may include classes of factors as described above.
  • the present invention includes a central nervous system neuronal cell survival factor having the following characteristics: (i) secreted by tectal cells grown in a pure in vitro culture, and
  • the invention also includes, in another aspect, a method of promoting survival and regeneration of damaged CNS neuronal cells, such as glutamatergic projection neurons or retinal ganglion cells, in a mammalian subject.
  • the method includes causing activation of protein kinase A in the damaged neuronal cells (e.g., pharmacologically or by electrical stimulation of the cells), and delivering a first growth factor to the cells.
  • the combination of activating protein kinase A and delivering the growth factor is effective to promote survival and regeneration of the cells.
  • the growth factor may be selected from the group consisting of insulin, brain-derived neurotrophic factor (BDNF), insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), neurotrophin-4/5 (NT-4/5), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), interleukin-6 (IL-6), basic fibroblast growth factor (bFGF), and transforming growth factor-alpha (TGF- ⁇ ).
  • the method includes also delivering a second growth factor.
  • the first growth factor may be selected from the group consisting of BDNF and NT-4/5
  • the second growth factor may be selected from the group consisting of CNTF, LIF and IL-6.
  • the method may be practiced by intraocular injection of, e.g., BDNF and CNTF, together with forskolin.
  • the method includes delivering first, second and third growth factors, where the growth factors may be selected from specific classes as described above.
  • the cells are glutamatergic projection neurons (e.g., retinal ganglion cells or cortical projection neurons), the first growth factor is selected from the group consisting of insulin, IGF-1 and IGF-2, the second growth factor is selected from the group consisting of BDNF and NT-4/5, and the third growth factor is selected from the group consisting of CNTF, LIF and IL-6.
  • the invention also includes a central nervous system neuronal cell survival factor having the following characteristics: (i) secreted by mature oligodendrocytes in a pure in vitro culture, (ii) sensitivity to heat inactivation by boiling for 5 minutes, (iii) sensitivity to inactivation by trypsin digestion, (iv) a molecular weight greater than approximately 10 kD, and (v) application of the factor to purified cultured postnatal retinal ganglion cells increases the survival time of the cells relative to cultured cells to which the factor is not applied.
  • Exemplary culture conditions for culturing the purified postnatal retinal ganglion cells include plating the cells on merosin-coated coverslips in a modified Bottenstein-Sato medium containing 5 ⁇ g/ml insulin, 5 ⁇ M forskolin, 50 ng/ml BDNF and 50 ng/ml CNTF.
  • the invention includes a method of promoting survival and regeneration of damaged central nervous system (CNS) neuronal cells in a mammdian subject.
  • the method includes (i) causing activation of cAMP-dependent protein kinase in the cells, and delivering a therapeutically effective amount of the oligodendrocyte factor described to the cells.
  • the combination of the activation of cAMP-dependent protein kinase and the delivering of the factor is effective to promote survival and regeneration of the cells.
  • the activation of cAMP-dependent protein kinase may include electrically stimulating the cells, such as by methods described above.
  • the cells may be glutamatergic projection neurons, such as cortical projection neurons or retinal ganglion cells.
  • the method may further include delivering an effective amount of a second growth factor (e.g., an insulin-like growth factor) to the cells, delivering a therapeutically effective amount of a second and a third growth factor (e.g., a neurotrophin) to the cells, or delivering a therapeutically effective amount of a second, a third and a fourth growth factor (e.g., a CNTF-like cytokine) to the cells.
  • a second growth factor e.g., an insulin-like growth factor
  • a third growth factor e.g., a neurotrophin
  • a fourth growth factor e.g., a CNTF-like cytokine
  • the invention includes a method of treating a brain disorder causing central nervous system (CNS) neuronal cell death or degeneration.
  • the method includes delivering to the cells, a dose of the oligodendrocyte-derived neurotrophic factor described above effective to reduce neuronal cell death or degeneration.
  • the disorder may be, for example, an acute injury to a portion of the central nervous system or a neurodegenerative disorder, such as Alzheimer's disease or amyotrophic lateral sclerosis.
  • the disorder may also be, for example, glaucoma, or a demyelinating disorder, such as multiple sclerosis.
  • the method may include activating a cAMP-dependent protein kinase (PKA) in the cells (e.g., by electrically stimulating the cells or by administering a pharmacological substance which, for example, acts to elevate intracellular cAMP levels or acts as a membrane-permeant analog of cAMP.
  • PKA cAMP-dependent protein kinase
  • Figures 1A, IB, IC, ID and IE show a schematic diagram of the panning procedure for purifying retinal ganglion cells.
  • Figures 2A shows dose-response curves of survival promoting effects of different concentrations of BDNF and CNTF on 3 day cultures of purified retinal ganglion cells (RGCs).
  • Figures 2B shows a bar graph indicating that combination of factors from 3 different classes produce additive effects on survival of RGCs in 3 day cultures.
  • Figure 3 shows that long-term survival of RGCs can be promoted by combinations of peptide trophic factors and cAMP elevating agents (survival measured at 3, 7, 14 and 28 days).
  • Figures 4A and 4B show the effects of cell density and basic fibroblast growth factor (bFGF) on RGC cell survival in 3 day cultures.
  • bFGF basic fibroblast growth factor
  • Figures 5A and 5B show exemplary photomicrographs of purified P8 retinal ganglion cells cultured for 14 days in the absence (Fig. 5A) or presence (Fig. 5B) of a conditioning layer of mature oligodendrocytes.
  • Figure 6 shows the survival of purified El 8 retinal ganglion cells cultured for 3 days in serum-free modified Bottenstein-Sato medium (MBS; described below) containing high insulin (5 ⁇ g/ml) and survival factors as assessed by the MTT assay.
  • MMS serum-free modified Bottenstein-Sato medium
  • Figure 7 shows the survival of purified El 8 retinal ganglion cells after 3 days of culture above a conditioning layer of various cell types in serum-free MBS medium containing forskolin (5 ⁇ M) and plateau levels of BDNF, CNTF, and insulin.
  • Figures 8A and 8B show the morphology of purified E18 retinal ganglion cells cultured for 3 days in serum-free MBS medium containing plateau concentrations of BDNF, CNTF, IGF-1 on merosin-coated wells in a 96-well plate with (Fig. 8B) or without (Fig. 8 A) conditioned medium from El 8 tectal cells.
  • Figure 9A shows the % survival of purified P8 retinal ganglion cells cultured in serum-free MBS medium for 2 days in the indicated survival factors with and without forskolin or potassium chloride.
  • Figure 9B shows the % survival of purified P8 RGCs cultured in serum-free MBS medium for 3 days in plateau levels of BDNF, CNTF and insulin, as well as forskolin, tetrodotoxin, kynurenic acid, NMDA and kainate (as indicated).
  • Figure 10 shown a field of purified postnatal retinal ganglion cells cultured in serum-free MBS medium containing BDNF, CNTF and IGF-1 for one week.
  • Figures 11A and 11B shown a field of purified postnatal 7-day cultures of RGCs immunostained with an anti-MAP-2 monoclonal antibody (Fig. 11 A) or an anti-tau monoclonal antibody (Fig. 11B).
  • Figures 12A and 12B shown electrophy ological records of action potentials in response to depolarizing current injection (Fig. 12A) and spontaneous excitatory postsynaptic currents (Fig. 12B) recorded from purified postnatal 7-day cultures of RGCs.
  • Figure 13 shows the % survival of Thy- 1 positive cerebral cortical neurons purified by immunopanning from postnatal day 8 rat cerebral cortices and grown in MBS medium containing BDNF, CNTF, insulin or forskolin, individually or in combination as indicated for 3 days.
  • a “defined medium” is a culture medium used for culturing a selected sample of cells, where the identities and concentrations of all of the components present in the medium are known prior to its addition to the sample of cells.
  • An exemplary defined medium is the serum-free modified Bottenstein-Sato medium (MBS; described below).
  • Serum added to a cell culture medium typically renders the resulting medium undefined, since the identity and concentration of all of the serum components is not ordinarily known.
  • the addition of "conditioned" medium to a cell culture medium renders the resulting medium undefined, since the identity and concentration of all of the components secreted by the conditioning cells into the conditioned medium are not generally known.
  • the term "defined conditions”, as applied to tissue culture refers to conditions employing a defined medium to grow a sample of cells in the absence of "feeder cells” (see below) or serum. For example, purified retinal ganglion cells grown in serum-free MBS medium in the absence of glial or other feeder cells are said to be grown under defined conditions.
  • feeder cells as applied to a culture of neuronal cells is understood to mean non-neuronal cells present in a culture to promote the survival, differentiation, growth or viability of the cultured neuronal cells.
  • fibroblasts plated as a confluent layer for use as a substrate for neuronal cells are considered to be feeder cells.
  • the glia are considered to be feeder cells.
  • a culture is considered to be a "pure" culture of a single cell type if greater that approximately 99% of the cells in that culture are of that cell type.
  • a culture containing 99.5% retinal ganglion cells and 0.5% glial cells is considered to be a pure culture of retinal ganglion cells.
  • a culture medium is considered to be “substantially serum-free” if the concentration of serum in the medium is insufficient to result in the medium having characteristics normally associated with a serum-containing medium. For example, many "undefined” media employ 5%-15% serum to promote the growth and survival of the cells with which they are used. If the serum concentration in such a medium is dropped below a threshold level (e.g., 2%), the medium may be no better at promoting cell growth and survival than a medium containing no serum. Such a medium is considered to be substantially serum-free. Of course, a medium containing no serum is also considered to be “substantially serum- free".
  • a substantially serum-free medium typically contains less than 2%, preferably less than 1 % , serum.
  • Treating refers to administering a therapeutic substance effective to reduce the symptoms of the disease and/or lessen the severity of the disease.
  • cAMP-dependent protein kinase e.g., elevation of intracellular levels of cAMP. Elevation of cAMP may be accomplished pharmacologically by including, for example, forskolin (a specific activator of adenylate cyclase) or chlorphenylthio-cAMP (a cell permeable synthetic analog of cAMP) in the culture medium.
  • forskolin a specific activator of adenylate cyclase
  • chlorphenylthio-cAMP a cell permeable synthetic analog of cAMP
  • cAMP pathway activation of the cAMP pathway is necessary and sufficient for responsiveness to all of the survival factors tested (including BDNF, CNTF, IGF-1, NT-4/5, LIF, IL-6, bFGF, TGF-alpha and ODNF), regardless of the factor's individual molecular mechanisms of action. Additionally, it was found that this cAMP pathway could be activated by depolarizing the CNS neurons (e.g., retinal ganglion cells), either by exposing them to elevated extracellular potassium or by applying glutamate agonists. With regard to promoting survival, these stimuli mimicked the effects of forskolin.
  • CNS neurons e.g., retinal ganglion cells
  • CNS neurons differ from PNS neurons in that CNS neurons need to be electrically active in order to respond to their trophic factors.
  • CNS neurons While not wishing to be bound by a particular mechanism for the workings of the present invention, it is contemplated that because injured CNS neurons lose their electrical activity or become entirely silent (as their synaptic inputs have been shown to strip off quickly after injury) following injury, they lose their ability to respond to the trophic factors that are essential for their survival and regeneration. This observation may explain why CNS neurons in vivo do not survive or regenerate after injury.
  • oligodendrocytes heretofore not known to secrete neurotrophic factors, can secrete a factor that is sensitive to heat inactivation and trypsin digestion, having a molecular weight greater than approximately 10 kD, and being effective to increase the survival time of retinal ganglion cells in culture.
  • This factor is contemplated to be useful in promoting regeneration and survival of damaged CNS neurons in vivo, and in treating brain disorders causing CNS neuronal cell death and/or degeneration.
  • All animals belonging to the phylum Chordata have a single, dorsal nerve cord comprising the central nervour. system (CNS).
  • this dorsal nerve chord includes the brain and the spinal cord.
  • the CNS acts together with the peripheral nervous system (PNS), which is composed of ganglia and peripheral nerves that lie outside the brain and spinal cord, to control virtually all aspects of an animal's behavior and response to sensory stimuli.
  • PNS peripheral nervous system
  • the central and peripheral nervous systems are separated anatomically, functionally they are interconnected and interactive (Kandel, et al. , 1991).
  • the peripheral nervous system has two divisions, somatic and autonomic.
  • the somatic nervous system includes neurons of the dorsal root and cranial ganglia that innervate the skin, muscles and joints and provide the CNS with information about limb position and external environment.
  • the axons of somatic motorneurons that innervate skeletal muscle and project to the periphery are often considered part of the peripheral nervous system, even though their cell bodies lie in the spinal cord (CNS).
  • the autonomic nervous system controls internal body functions, including the viscera, smooth muscle and exocrine glands, and consists of three parts - the sympathetic system, parasympathetic system and enteric system.
  • the sympathetic system participates in the body's response to stress, whereas the parasympathetic system acts to restore homeostasis.
  • the enteric nervous system controls the function of the smooth muscle of the gut.
  • the central nervous system receives sensory information (typically via the PNS) from sensory organs, such as the eyes, ears and receptors within the body, analyzes the information, and initiates an appropriate response (e.g., moving a muscle).
  • the CNS also initiates responses aimed at satisfying certain "drives". Some, such as the drive for survival, are basic and are initiated unconsciously or automatically ("fight or flight” response). Others are more complex, and revolve around the need to experience positive emotions (e.g., pleasure, excitement) and avoid negative ones (e.g, pain, anxiety, frustration).
  • the central nervous systems consists of six main regions: (i) the spinal cord, (ii) the medulla, (iii) the pons and cerebellum, (iv) the midbrain, (v) the diencephalon, and (vi) the cerebral hemispheres.
  • the spinal cord is the simplest and most caudal part of the CNS. It extends from the base of the skull through the first lumbar vertebra, receives sensory information from the periphery of the trunk and limbs, and contains the motor neurons responsible for voluntary as well as reflex movements. It also receives some sensory information from internal organs and is involved in the control of many visceral functions.
  • the medulla, pons, cerebellum and midbrain are collectively termed the brain stem.
  • the brain stem is positioned between the spinal cord and the diencephalon, and is concerned, in part, with sensation from the skin and joints in the face and neck, as well as with hearing, taste and balance.
  • Motor neurons in the brain stem control the muscles of the head and neck.
  • the brain stem also contains ascending and descending pathways that carry sensory and motor information to and from higher brain regions (Kandel, et al, 1991).
  • the diencephalon consists of the thalamus and hypothalamus.
  • the thalamus processes and distributes most of the sensory and motor information going to the cerebral cortex, and may regulate levels of awareness and emotional aspects of sensory experiences.
  • the hypothalamus regulates the autonomic nervous system and hormonal secretion by the pituitary gland (Kandel, et al, 1991).
  • the cerebral hemispheres form the largest region of the brain. They consist of the cerebral cortex (mostly cell bodies), the underlying white matter (nerve fibers), and three deep-lying nuclei - the basal ganglia, the hippocampal formation and the amygdala.
  • the cerebral hemispheres are divided by the interhemispheric fissure and are concerned with perceptual, cognitive and higher motor functions, as well as emotion and memory (Kandel, et al, 1991).
  • the visible part of the cerebral cortex that forms the highly convoluted surface of the cerebral hemisphere is called the neocortex, and may be divided into six distinct layers, termed I through VI.
  • Layer I consists mostly of fibers, level II contains small pyramidal cells and level III contains large pyramidal cells. Both layers II and III project to and receive input from other cortical areas, as well as receiving input from layer IV.
  • the pyramidal cells comprising levels II and III are almost exclusively glutamatergic, and due to the relatively distal aspect of their targets, are termed glutamatergic projection neurons.
  • Layer IV consists primarily of stellate cells which receive input from the thalamus and project to other layers of the cortex.
  • Layer V contains large pyramidal cells which receive input from layer IV and project to the brainstem and spinal cord, while layer VI contains medium pyramidal cells, which receive input from the thalamus and other cortical areas and project to the thalamus.
  • the pyramidal cells of layers V and VI are also considered glutamatergic projection neurons. In fact, nearly all projection neurons in the mammalian brain are glutamatergic projection neurons.
  • certain sensory organs such as the retina of the eye, are considered, anatomically, to belong to the central nervous system.
  • the retina contains five major classes of neurons (photoreceptors, bipolar cells, horizontal cells, amacrine cells and ganglion cells) arranged in an orderly layered arrangement and linked together in an intricate pattern of connections.
  • the outer layer contains the photoreceptor cells (rods and cones), which hype ⁇ olarize in response to light and communicate this signal through a group of interneurons (bipolar, horizontal and amacrine cells) to the ganglion cells.
  • Ganglion cells are the output neurons of the retina, and have glutamatergic synapses (i.e., they are glutamatergic projection neurons).
  • tectum in rats is analogous to the superior colliculus in primates; in fact, some investigators refer to the rat tectum as "superior colliculus”.
  • Neurons Neurons, or nerve cells, carry the electrical signals that underlie he functioning of the brain.
  • the human brain contains about 10" neurons.
  • nerve cells may be classified into perhaps as many as 10,000 different types, they share many common features (nerve cells with very similar cellular properties may produce very different actions, and therefore be functionally classified as distinct types of cells, depending on their precise connections with each other and their connections with sensory receptors and muscle).
  • the neurons can be classified functionally into three distinct groups — afferent neurons, motor neurons and interneurons.
  • Afferent, or sensory neurons carry information into the CNS for conscious perception and motor coordination, while motor neurons carry commands to muscles and glands.
  • Interneurons constitute by far the largest number of neurons in the brain. They can be divided into two groups. Projection, or relay interneurons (also termed Golgi type I cells) relay information over long distances, from one brain region to another, and accordingly have very long axons.
  • Local interneurons also termed Golgi type II cells process information within specific subregions of the brain and have relatively short axons (Kandel, et al, 1991).
  • Neurons are specially constructed to facilitate the conduction and processing of information.
  • a typical neuron has four mo ⁇ hologically defined regions: (i) the cell body, or soma, consisting of the nucleus and perikaryon, (ii) dendrites, (iii) an axon, and (iv) presynaptic terminals.
  • the axon and dendrites are processes that extend from the cell body.
  • the dendrites typically branch out in a tree-like fashion and serve as the main input of information from other nerve cells.
  • the axon is a tubular process ( ⁇ 0.2 to 20 ⁇ m in diameter) that can ramify and extend for up to one meter in humans.
  • the branches of the axon from a single neuron may form synapses with 1000 or more other neurons, while the dendrites and cell body of a single neuron (e.g., a Purkinje cell of the cerebellum) may receive contacts from over 150,000 other cells. Near its end, the axon divides into fine branches with specialized endings termed presynaptic terminals.
  • the presynaptic terminals are the sites at which the neuron transmits its information to another cell (the postsynaptic cell).
  • the postsynaptic cell may be another neuron, a muscle or a secretory (gland) cell.
  • the point of contact is termed the synapse.
  • presynaptic terminals typically terminate near the postsynaptic neuron's dendrites, although they may terminate at the cell body or at the initial segment of the postsynaptic axon.
  • Mammalian CNS synapses are typically chemical in nature — that is, they function by the presynaptic releasing a chemical neurotransmitter into the synaptic cleft. The neurotransmitter activates receptors in the postsynaptic cell membrane, which initiate a corresponding electrical or chemical (i.e., calcium) signal in the postsynaptic cell.
  • Neurotransmitters used in the brain include glutamate and glutamate-like compounds, GABA, acetylcholine, catecholamines. Most neurons utilize a single neurotransmitter to communicate with other neurons or effector organs. Approximately 70% of the neurons in the human brain are glutamatergic, and -30% are GABAergic. Less than one percent of the neurons use acetylcholine or catecholamines as transmitters (Peters, et al., 1991).
  • the CNS neurons that communicate signals from the retina of the eye to the brain are termed retinal ganglion cells (RGCs).
  • RGCs retinal ganglion cells
  • Retinal ganglion cells are generated in the rat embryonic retina approximately between El 3 and El 8 (reviewed in Jacobson, 1991).
  • RGCs innervate the optic tectum (Linden and Perry, 1983).
  • Their axons reach the tectum between E18 to P2 and establish a mature pattern of topographically correct tectal connections by about P8 (Simon and O'Leary, 1992).
  • the retinal ganglion cells are typically generated between approximately E40 and E50.
  • Nerve cell bodies and axons are surrounded by glial cells.
  • Glial cells of the vertebrate nervous system may be classified into two groups - microglia and macroglia.
  • Microglia are phagocytes mobilized after injury, infection or disease. They are derived from macrophages, and are unrelated (physiologically and embryologically) to the cells of the central nervous system. Accordingly, the discussion herein is concerned with macroglia.
  • Macroglia include three predominant types, two of which (oligodendrocytes and astrocytes) are present in the central nervous system (Kandel, et al, 1991).
  • Oligodendrocytes are relatively small cells that form myelin sheaths around axons of the CNS by wrapping their processes concentrically around an axon in a tight spiral. A single oligodendrocyte typically envelopes several different axons (average of 15). Astrocytes typically have irregularly-shaped bodies and relatively long processes.
  • astrocytes serve as supporting cells for neurons, providing structure to the brain and separating groups of neurons from one another. Others contact endothelial cells of blood vessels in the brain, stimulating the endothelial cells to form tight junctions, which form the "blood-brain barrier". Still others are involved in absorbing excess extracellular potassium or neurotransmitters released during episodes of high neuronal activity.
  • Optic nerve astrocytes may be further classified into type I and type II astrocytes.
  • Type I astrocytes are the main type of white matter astrocytes in vivo. Their processes contact nodes of Ranvier and blood vessels.
  • Type II astrocytes are commonly found in vitro in CNS cultures, but are not normally observed in vivo. It is possible that type II astrocytes are induced following injury.
  • glial cells can also serve to secrete certain survival factors required to prevent the neurons from undergoing apoptosis.
  • astrocytes and Schwann cells have previously been found to secrete a variety of neurotrophic factors, including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and insulin-like growth factor 1 (IGF-1), there has heretofore been no evidence to suggest that oligodendrocytes, the myelinating cells of the CNS, secrete neurotrophic factors.
  • BDNF brain-derived neurotrophic factor
  • CNTF ciliary neurotrophic factor
  • IGF-1 insulin-like growth factor 1
  • the teachings provided herein enable one of skill in the art to maintain cultures of pure CNS neuronal cells under defined conditions for extended periods of time. These conditions include growing or maintaining the cells under conditions effective to stimulate cAMP-dependent protein kinase in the cellr. and providing at least one trophic growth factor. As will be discussed more fully below, the inclusion of one growth factor effectively promotes short-term (3 day) survival of approximately >30% of such CNS neuronal cells. The inclusion of a second factor, preferably one from a different "class” than the first factor (see below), increases the rate of survival relative to that seen with a single factor. Similarly, adding a third factor, preferably from still another "class”, extends the survival beyond that seen with two factors.
  • Results of experiments detailed in Example 1 illustrate these relationships. Individual growth factors were applied either in isolation (one factor per experiment) or in combination (two or more factors per experiment) to cultures of purified rat retinal ganglion cells. The factors were applied with or without forskolin, a compound which activates adenylate cyclase and thereby increase intracellular levels of cAMP.
  • Example 1 Also detailed in Example 1 are experiments measuring the dose-response curves of the survival-promoting ability of BDNF and CNTF (in the presence of forskolin and insulin) on purified RGCs.
  • the first class termed insulin-like growth factors, includes insulin, insulin-like growth factor 1 (IGF-1; previously referred to as somatomedin C) and insulin-like growth factor 2 (IGF-2; previously referred to as Multiplication Stimulating Activity).
  • IGF-1 and IGF-2 share about 76% sequence identity with each other and about 50% sequence identity with proinsulin.
  • IGF-1 is thought to be an autocrine regulator of skeletal growth and whole-body protein metabolism, while IGF-2 is thought to be involved in fetal development (LeRoith and Roberts, 1993; Lowe, 1991). Both IGF-1 and IGF-2 are nonglycosylated single-chain peptides, 70 and 67 amino acid residues in length, respectively.
  • neurotrophins The second class of growth factors, termed neurotrophins, includes brain-derived neurotrophic factor (BDNF) and neurotrophin 4/5 (NT-4/5).
  • BDNF brain-derived neurotrophic factor
  • NT-4/5 neurotrophin 4/5
  • BDNF brain-derived neurotrophic factor
  • NT-4/5 neurotrophin 4/5
  • BDNF brain-derived neurotrophic factor
  • NT-4/5 neurotrophin 4/5
  • BDNF brain-derived neurotrophic factor
  • NT-4/5 was originally isolated from Xenopus and viper DNA (Halbook, et al., 1991).
  • the equivalent mammalian gene, also known as NT-5 was subsequently isolated from rat and human DNA (Halbook, et al, 1991; Ip, et al., 1992).
  • NT-4/5 shares a 50-60% amino acid homology with other members of the neurotrophin family
  • CNTF-like cytokines includes ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF) and interleukin-6 (IL-6). Oncostatin M (OSM) and interleukin- 11 (IL-11) may also be considered to be CNTF-like cytokines.
  • CNTF was initially purified from chick eye, and has been demonstrated to have survival-promoting activity on chick ciliary, dorsal root sensory and sympathetic ganglia (Barbin, et al., 1984).
  • Human IL-6 cDNA encodes a 212 amino acid precursor that is cleaved to produce a mature protein (minus the N-terminal signal peptide) of 184 amino acids and a molecular weight of 21 kDa.
  • IL-6 is expressed by a variety of cells, including astrocytes, and has been shown to stimulate growth in a number of systems.
  • LIF is pleiotropic cytokine initially identified as a factor that could inhibit proliferation and induce macrophage differentiation in the murine myeloid leukemic cell line Ml (Gearing, et al , 1987).
  • Figure 2B Exemplary results are summarized in Figure 2B, which shews the effects of combining survival factors on short term (3 day) retinal ganglion cell survival. All factors were used at plateau concentrations (concentrations providing the maximum percent survival in assays such as shown in Fig. 2A). Insulin plus BDNF, for example, was better than insulin or BDNF alone, while insulin plus BDNF and CNTF was better than any two of these alone. The majority of the cells could be saved for at least 3 days by the combination of forskolin, insulin, BDNF, CNTF and growth on a merosin-coated surface.
  • a pure serum-free culture of healthy CNS neurons may be maintained for at least 28 days. Further, the rate of change of survival as a function of time in these studies suggests that the majority of cells may be able to survive under such conditions for up to 60 days, with at least 30% surviving upwards of several months. Exemplary results of experiments to this effect are detailed in Example IC and shown in Fig. 3.
  • the trophic factors employed in the present experiments are secreted by cells that (in situ) normally contact the CNS neurons being cultured.
  • Such contacting cells include glial cells (astrocytes and oligodendrocytes) as well as cells with which the neurons forms synaptic connections (presynaptic cells and postsynaptic cells).
  • Examples of effective survival factors secreted by neighboring cells included BDNF (made by the tectum), CNTF or LIF (made by optic nerve astrocytes and tectum; Stockli, et al, 1991; Yamamori, 1091; Patterson and Fann, 1992), and IGF-1 (made by astrocytes; Ballotti, et al., 1987; Hannson, et al., 1989; Rotwein, et al , 1988; Baron-van Evercooren, et al, 1991).
  • BDNF made by the tectum
  • CNTF or LIF made by optic nerve astrocytes and tectum
  • Stockli, et al, 1991 Yamamori, 1091; Patterson and Fann, 1992
  • IGF-1 made by astrocytes; Ballotti, et al., 1987; Hannson, et al., 1989; Rotwein, et al , 1988; Baron-van Evercooren, et al, 1991).
  • CNS neurons such as RGCs
  • long-term survival of CNS neurons depends on a collaboration of astrocyte, oligodendrocyte and target-derived factors, as well as stimulation of cAMP-dependent protein kinases in the cells (e.g., by elevation of intracellular cAMP, accomplished, e.g., by forskolin).
  • the data discussed above suggest that the requirement for multiple trophic factors for long-term survival does not reflect the presence of multiple subsets of cells, each with different trophic factor sensitivities, but rather, that multiple factors act collaboratively on individual RGCs to promote their long-term survival.
  • Thy-1 which was originally found on thymocytes (Williams and Gagnon, 1982), is expressed on mature glutamatergic projection neurons, such as retinal ganglion cells and cerebral cortical glutamatergic projection neurons, and may be used to purify such cells (as detailed below) as well as to identify them from other cell types, and to assess their general conditions (i.e., healthy, differentiated glutamatergic projection neurons express Thy-1).
  • Thy-1 is a major brain glycoprotein found on the surface of many neurons, and is a member of the Ig superfamily.
  • MAP-2 refers to microtubule-associated protein 2, an intracellular cytoskeletal protein that is expressed in the dendrites of a wide variety of CNS neurons, but is not expressed in non-neuronal cells (Kosik and Finch, 1987). When neurons in culture lose viability, they typically retract their dendrites and stop expressing MAP-2. Tau is expressed in the axons of a wide variety of neurons, but like MAP-2, is not expressed in non-neuronal cells. Tau is also an intracellular cytoskeletal protein, and may be used as a marker for healthy CNS neurons.
  • Example 7 Examples of the use of anti-MAP-2 and anti-tau antibodies to stain CNS neurons are presented in Example 7.
  • the primary antibodies were detected with an FITC-conjugated anti-mouse IgG antibody.
  • the cells clearly express the neuronal markers MAP-2 and tau.
  • optic nerve type-1 astrocytes express an unknown cell membrane protein termed RAN-2 (rat neural antigen 2; Bartlett, et al., 1981), oligodendrocyte precursor cells express the ganglioside A2B5 (Eisenbarth, et al, 1979), and mature oligodendrocytes express galactocerebroside glycolipid (GC; Ranscht, et al, 1982).
  • RAN-2 rat neural antigen 2
  • oligodendrocyte precursor cells express the ganglioside A2B5 (Eisenbarth, et al, 1979)
  • mature oligodendrocytes express galactocerebroside glycolipid (GC; Ranscht, et al, 1982).
  • Antibodies directed against these cell surface markers may be used to purify the respective cell populations, as described below, and to identify the cells using, for example, immunohistochemistry.
  • electrophysiological approaches may also be employed.
  • patch clamp recording may be used to characterize the distribution and types of ion channels present in the cell membrane, or to record the membrane response to depolarizing stimuli, as detailed, e.g., in Example 7.
  • Methods of the present invention may be employed to culture both embryonic (prenatal) CNS neurons as well as postnatal CNS neurons.
  • both types of cells need trophic growth factors as well as conditions effective to stimulate intracellular cAMP-dependent protein kinases (e.g., elevated intracellular cAMP).
  • the specific types of trophic factors required may differ between the two cell types, however.
  • neurons that have not yet contacted their targets at the time they are removed from an organism for culturing typically require trophic factors produced by the target cells. Further, such cells may have altered requirements (relative to postnatal cells) for other trophic factors, such as factors of the CNTF-like cytokine family.
  • Example 5 also demonstrate, however, that a high degree of survival (>75% at 3 days) may be obtained if the cells are cultured in the presence of medium conditioned by purified tectal cells (Fig. 7).
  • the survival of the El 8 RGCs was enhanced nearly 5-fold (relative to no treatment) by soluble tectal factors.
  • the results indicate that the tectum secretes a significant survival activity which, according to additional experiments performed in support of the present invention, was not mimicked by known neurotrophins, including nerve growth factor (NGF), BDNF, neurotrophin-3 (NT-3), and NT4/5.
  • NGF nerve growth factor
  • BDNF nerve growth factor
  • NT-3 neurotrophin-3
  • NT4/5 neurotrophin4/5.
  • FIGs. 8 A and 8B Photomicrographs of the purified El 8 retinal ganglion cells in the absence and presence of tectal medium are shown in Figs. 8 A and 8B, respectively. Whereas the majority of cells grown in the absence of the tectal medium died by three days of culture, the majority of those grown in the presence of the tectal conditioned medium thrived and extended processes.
  • trophic factors that are synthesized by those targets may be employed in the practice of the present invention to promote the survival of cultures of such neurons, and to promote survival and regeneration of damaged CNS neurons in vivo.
  • target-derived factors may be used in addition to factors discussed above, or in certain cases, in place of a representative factor from one of the three classes discussed above. Experiments detailed below demonstrate how one of skill in the art may determine the minimal required combination of factors for promoting survival.
  • an important aspect of promoting the survival of pure cultures of CNS neurons under chemically-defined (e.g., serum-free) conditions is the activation of cAMP-dependent protein kinase (protein kinase A; PKA) in the cells.
  • cAMP-dependent protein kinase protein kinase A
  • Such activation is typically accomplished by elevation of intracellular cAMP levels or the application of a cAMP analogue effective to activate cAMP-dependent protein kinase.
  • Forskolin activates adenylate cyclase, the enzyme that synthesizes cAMP, thereby directly increasing intracellular levels of cAMP.
  • Forskolin was employed in RGC experiments detailed in Examples 1-7 and 9, and in cortical neuron experiments detailed in Example 8. The addition of forskolin to the culture medium generally resulted in a 6-10 fold increase in the percent survival relative to no forskolin.
  • Example 8 show typical results of forskolin.
  • Thy-1 positive cerebral cortical neurons were plated in MBS medium containing BDNF, CNTF, insulin and forskolin, individually or in combination as indicated, and their survival plotted along the y-axis.
  • a number of other methods may be used to stimulate cAMP-dependent protein kinase.
  • experiments described herein demonstrate that depolarizing the cells in the presence of physiological levels (about 200 ⁇ M to 10 mM) of extracellular calcium is effective to confer the same potentiation on survival caused by forskolin.
  • the depolarization may be achieved by increasing the extracellular potassium concentration, as illustrated in Example 6 and Fig. 9A, by activating glutamate receptors using a cocktail of glutamate receptor agonists, as illustrated in Example 6, Fig. 9B, or by other means, such as electrical stimulation.
  • cAMP-dependent protein kinase inhibitor a cAMP-dependent protein kinase inhibitor
  • Cell culture techniques which have been employed in the past by skilled artisans to enhance growth and differentiation of cells in serum-containing media may also be employed with methods of the present invention to further enhance the growth and differentiation of purified CNS neurons grown under defined conditions.
  • appropriate choice of substrate is an important aspect of cell survival.
  • the defined components added to the serum-free media described herein is important for optimal neuronal cell survival.
  • the components identified in Table 1, particularly progesterone, tri-iodothyronine and thyroxine are important contributors to CNS neuronal cell survival.
  • CNS neuronal cells under defined conditions may also be also affected by soluble factor(s) released by the neuronal cells themselves. For example, it is known that for certain cultures that survival time can be increased by increasing the density at which the cells comprising the cultures are plated. This density effect on survival is presumably due to trophic factors, secreted by the cultured cells, that need to be present above a threshold concentration for optimal cell survival. According to the teachings herein, such factors may be added to neuronal cultures of the present invention to further promote survival of the cells, particularly if the cells are plated at low densities.
  • the support on which the cells are plated can also have a significant effect on cell survival.
  • the survival of CNS neurons plated on glass is significantly worse than the survival of the same cells plated on plastic (e.g., tissue culture plastic), other factors being equal.
  • This difference is exemplified in the difference in survival rates shown in Figure 3 (plated on plastic) vs the survival rates indicated in Table 3 (plated on glass).
  • the survival rate for RGCs in Table 3 at 3 days in medium containing forskolin, CNTF, BDNF, and insulin was 55%
  • the survival rate for the same cells grown in the same medium, but plated on plastic was 80% at 3 days (Figure 3).
  • CNS cells The experiments detailed herein have employed two exemplary types of CNS neurons, retinal ganglion cells and cortical projection neurons, to demonstrate survival and growth factor requirements of the present invention which may be applied to the culture of CNS neuronal cells in general. Both retinal ganglion cells and cortical projection neurons can be classified as glutamatergic projection neurons, a broad category which includes approximately 70% of the neurons in the human brain. The fact that, according to the teachings herein, these two cell types have essentially identical growth and survival requirements, despite their different presynaptic inputs, locations and target cells in the CNS, suggests that the conditions detailed herein for their growth and survival may be applied to other types of CNS neurons.
  • retinal ganglion cells and the cortical projection neurons share, along with essentially all the other neurons of the central nervous system, intimate contact with astrocytes and oligodendrocytes, the two basic types of glial cells present in the central nervous system.
  • CNS neuronal cell requirements for specific factors may differ somewhat as a function of the cells's developmental stage at time of isolation (i.e., whether or not the cell had innervated its target)
  • the basic teachings herein regarding CNS neuronal cell survival i.e., PKA activation w/trophic factors
  • PKA activation w/trophic factors apply to all CNS cells.
  • the inclusion of, for example, one factor from each of the 3 factor classes described above effectively promotes survival of the cultures.
  • survival of the cells may be promoted using three different factors as described above, and in cases of cells that had not yet innervated their targets, may be further promoted by the addition of a factor or factors derived from those targets.
  • the survival and growth conditions determined from the in vitro culture experiments described herein may be applied to promote the survival, growth and regeneration of injured CNS neurons in vivo.
  • a CNS neuronal injury such as injury caused by acute trauma, ischemia/reperfusion, neurodegenerative disease, and the like
  • the injured neurons typically retract their axons and commit apoptosis.
  • Presynaptic cells which terminate on the injured neuron withdraw their inputs, and glial cells contacting the injured neuron die.
  • Injury resulting in interruption of axons in the adult mammalian CNS leads to a persistent neurological defect, such as paralysis or blindness, because of the failure of the CNS to repair itself.
  • injury to RGC axons leads to blindness because of death and permanent loss of the RGCs and their axons (Berkelaar, et al., 1994).
  • Growth factors may be delivered to CNS neurons in vivo using a number of methods.
  • local application to a site of acute injury may be via a direct injection to the affected site (e.g., intraocular injection for promoting retinal ganglion cell survival following optic nerve injury or injection into the cerebrospinal fluid for promoting survival of cells with damaged axons following spinal cord injury).
  • the injections may be administered periodically until the injury has been effectively treated.
  • the factors may also be delivered systemically (e.g., intravenous injection), particularly in cases where the blood- brain barrier is compromised or broken-down, such as may occur in trauma or inflammatory disease (e.g., multiple sclerosis).
  • Cells secreting recombinant factors may also be administered to deliver selected factors following, e.g., an acute CNS injury. Such cells can effectively secrete the desired factors for over two weeks, facilitating healing of the injured tissue.
  • a cell-mediated delivery approach such as described above has been used successfully to deliver proteins as large as antibodies throughout the CNS. For example, Schnell and Schwab (1990) showed that when antibody-secreting hybridoma cells are injected into postnatal rat brain, the antibodies are secreted into the spinal fluid and delivered throughout the brain, optic nerve and retina.
  • Peptide trophic factors can be delivered using similar approaches by injecting cells that had been transiently or stably transfected with a vector containing peptide trophic factor DNA sequences in a manner effective to cause the cells to secrete the recombinant trophic factor into the subarachnoid space (Barres, et al. , 1992, 1993, 1993a, 1994; Barres and Raff, 1993; Example 13).
  • Such cells sink to the basilar meninges overlying the optic chiasm and continuously deliver trophic factors at high levels into the optic nerve for at least two weeks.
  • This approach is simple, has a high success rate, and causes no apparent discomfort to the postnatal rat pups in which it was employed.
  • transfected cells can deliver secreted factor for at least 10 to 14 days, ample time to allow significant regeneration to occur (axon regeneration should occur at the rate of slow axonal transport, which is 1 mm per day; the postnatal optic nerve is less than 10 mm long).
  • the factors may also be introduced using gene therapy approaches. Such modes of administration may be particularly suitable for the delivery of factors in cases of chronic neurological disorders, such as ALS, Alzheimer's disease or multiple sclerosis.
  • DNA sequences encoding the desired factors are cloned into a suitable expression vector effective to express the factor in selected host cells.
  • RGCs may be directly targeted with a replication-deficient he ⁇ es virus vector containing DNA sequences encoding a desired growth factor.
  • He ⁇ es virus vectors (Breakefield and DeLuca; Freese, et al.) are particularly well suited for the delivery and expression of foreign DNA in cells of the CNS, since they can efficiently infect mature, postmitotic neurons.
  • He ⁇ es virus vectors have additional advantages for CNS regeneration therapy. For example, failure of the upper motor neurons (pyramidal glutamatergic projection neurons that synapse onto the lower motor neurons in the spinal cord) to regenerate their axons is the main cause of paralysis after a spinal cord injury. Since he ⁇ es viruses can be retrogradely transported, the upper motorneurons may be targeted by local injection of an injured corticospinal tract. He ⁇ es virus vectors capable of expressing appropriate growth factors can be administered in this way under conditions which stimulate PKA in the injured cells to promote regeneration and reduce or eliminate paralysis following spinal cord injury.
  • appropriate expression vectors may be used to transfect glial cells (in vivo or in vitro), such as astrocytes or oligodendrocytes, to produce cells capable of secreting a desired recombinant growth factor.
  • glial cells in vivo or in vitro
  • Cells transfected with different factors may be used together in the methods of the present invention to deliver multiple factors to the same site.
  • Cells transfected in vitro may be transplanted back into the region of the brain in need of treatment as described above. Transfected cells secrete the desired factors and promote survival of the degenerating neurons.
  • Protein kinase A may be stimulated in vivo by pharmacological approaches, genetic approaches or electrical stimulation.
  • the injured cells may be stimulated with a stimulating electrode (e.g., an implanted electrode), or by administration of an agent effective to depolarize the injured cells (e.g., a glutamate agonist, or preferably, a mixture of glutamate agonists).
  • a stimulating electrode e.g., an implanted electrode
  • an agent effective to depolarize the injured cells e.g., a glutamate agonist, or preferably, a mixture of glutamate agonists.
  • An exemplary implantable electrode suitable for electrical stimulation of retinal ganglion cells has been described (Roush). Electrodes suitable for the stimulation of other CNS regions, such as spinal cord, are also known.
  • PKA may be stimulated by pharmacologically elevating cAMP levels in the injured neurons, such as by injecting, for example, forskolin, CPTcAMP or 8- Bromo-cAMP periodically to the affected site.
  • Methylxanthines such as caffeine and theophylline, are clinically-approved drugs that may also be used to elevate intracellular cAMP concentrations.
  • methods of the present invention may be used to grow pure cultures of CNS neurons under defined conditions for use in screening of therapeutic substances.
  • Such screens should be as uniform as possible to allow standardization of test results. It is well known in the art, however, that the physiological characteristics and/or patterns of gene expression in cultured cells grown in the presence of serum often differ depending on the lot of serum used. Such inconsistencies may result in irreproducible or erroneous screening results, leading significant downtime and ensuing economic losses as the source of the variability in cell is traced down.
  • the retinal ganglion cell data exemplified herein are particularly relevant to humans and human conditions, since rat optic nerve has a structure that is very similar to that of humans (Kennedy, et al., 1986). All of the three main types of glial cells found in rat optic nerve are found in human optic nerve. Many of the antibody markers used to study rat optic nerve also identify human optic nerve glia. Thus, these experiments are directly relevant to understanding the function and pathophysiology of human glia.
  • oligodendrocvte-Derived Neurotrophic Factor whereas both astrocytes and Schwann cells have previously been found to secrete a variety of neurotrophic factors including brain-derived neurotrophic factor (BDNF), ciliary neurotrophic factor (CNTF), and insulin-like growth factor 1 (IGF-1) (Stockli, et al. , 1991, Yamamori, 1991, Patterson and Fann, 1992, Ballotti, et al., 1987, Hannson, et al., 1989, Rotwein, et al., 1988), there has heretofore been no evidence that oligodendrocytes, the myelinating cells of the CNS, secrete neurotrophic factors.
  • BDNF brain-derived neurotrophic factor
  • CNTF ciliary neurotrophic factor
  • IGF-1 insulin-like growth factor 1
  • oligodendrocytes can secrete a trypsin-sensitive, heat-sensitive factor that promotes the survival of CNS neurons cultured under defined conditions.
  • the factor was identified by culturing purified P8 RGCs over a conditioning layer of highly purified postnatal optic nerve astrocytes (>99.5% pure), immature oligodendrocytes (oligodendrocyte precursor cells purified to greater than 99.95% purity), or mature oligodendrocytes (immature oligodendrocytes aged for 10 days), in the presence of insulin, forskolin and other factors as indicated and assessing cell survival after 3 days of culture.
  • oligodendrocyte-derived neurotrophic factor referred to as oligodendrocyte-derived neurotrophic factor; ODNF
  • NGF oligodendrocyte-derived neurotrophic factor
  • GDNF glial cell-derived neurotrophic factor
  • IL-7 IL-7
  • IL-3 growth hormone (GH) and glial growth factor (GGF)
  • ODNF was further characterized as detailed in Example 9.
  • Serum-free MBS medium containing was conditioned by a dense culture of mature oligodendrocytes for at least three days, and subjected to one of three treatments. One sample of the serum was boiled for 5 minutes to heat-inactivate proteinaceous activity, another sample was incubated in a solution of trypsin-coupled beads, and a third sample was centrifuged through a concentrator membrane which excluded molecules greater than 10 kD. These medium samples were then tested for their ability to promote survival purified P8 retinal ganglion cells plated on merosin-coated wells in a 96-well plate as described in Example 9.
  • oligodendrocyte-derived neurotrophic factor is a trypsin-sensitive heat-sensitive > 10 kD proteinaceous factor secreted by oligodendrocytes.
  • One of skill in the art having the benefit of the present disclosure may proceed to obtaining the cDNA sequence encoding the factor using techniques known to those skilled in the art (e.g., Ausubel, et al.,; Sambrook, et al.).
  • Example 10 describes the synthesis of a cDNA library which may be used to isolate the ODNF cDNA using expression cloning.
  • the library was prepared in the expression vector pMET7 (Takabe, 1988), containing the highly efficient SR alpha promoter (Kriegler, 1990), from poly-A + mRNA isolated from highly purified (> 99.95% pure) mature oligodendrocytes. It contains over one million independent recombinants with an average insert size 1.6 kB.
  • Other suitable expression vectors such as pSG5 (Green, et al., 1988; Stratagene, La Jolla, CA), may also be used for the construction of such a library.
  • a cDNA made from mature oligodendrocytes maybe screened using methods known to those skilled in the art to identify clones encoding ODNF. For example, an expression screening approach, such as is detailed in Example 10, may be employed.
  • the library is amplified and divided into pools, from which groups of plasmids are isolated for transfection using lipofectamine (or DEAE Dextran) into eukaryotic cells, such as COS7 cells.
  • conditioned medium from the transfected cells is collected and assayed for survival-promoting activity (as described above) on purified postnatal RGCs. Pools of cells that enhance survival are then subcioned and rescreened until individual clones having survival activity are identified.
  • ODNF clones identified maybe further characterized, manipulated and expressed to generate recombinant ODNF.
  • cDNA clones encoding the RGC survival activity (ODNF) are isolated, sequenced, and the sequences compared for homologies to known sequences.
  • Northern blot and in situ hybridization analyses may be performed to verify that the mRNAs are expressed specifically by oligodendrocytes but not astrocytes.
  • Recombinant ODNF polypeptides may be produced using a clone encoding the full- length ODNF (the clone may isolated as a full length clone or assembled from overlapping partial clones).
  • the recombinant polypeptides may be prepared as fusion proteins, by cloning ODNF cDNA polynucleotide sequences into an expression plasmid, such as pGEX, to produce corresponding polypeptides.
  • the plasmid pGEX Smith, et al., 1988
  • its derivatives express the polypeptide sequences of a cloned insert fused in-frame with glutathione-S-transferase.
  • the recombinant pGEX plasmids is transformed into an appropriate strains of E. coli and fusion protein production is induced by the addition of IPTG (isopropyl-thio galactopyranoside). Solubilized recombinant fusion protein is then purified from cell lysates of the induced cultures using glutathione agarose affinity chromatography according to standard methods (Ausubel, et al.).
  • Affinity chromatography may also be employed for isolating /3-galactosidase fusion proteins.
  • the fused protein is isolated by passing cell lysis material over a solid support having surface-bound anti-/3-galactosidase antibody.
  • Isolated recombinant polypeptides produced as described above may be purified by standard protein purification procedures, such as differential precipitation, molecular sieve chromatography, ion-exchange chromatography, isoelectric focusing, gel electrophoresis and affinity chromatography, and used for subsequent experiments, such as generation of antibodies (Harlow, et al.).
  • Antibodies directed against the RGC survival factor may be used for immunolocalization of this protein and/or to block the oligodendrocyte-derived survival activity.
  • the recombinant protein may also be used to promote the survival of retinal ganglion cells in culture, as well as to promote the survival and axonal regeneration of glutamatergic projection neurons, such as retinal ganglion cells, in vivo following neuronal injury.
  • the results discussed above indicate that oligodendrocytes synthesize and secrete a novel neurotrophic factor, and that this factor promotes the long-term survival of retinal ganglion cells. Since most other types of CNS neurons are myelinated by oligodendrocytes, it is contemplated that the oligodendrocyte neurotrophic factor promotes the survival of all such oligodendrocyte-myelinafed CNS neurons.
  • the oligodendrocyte-derived neurotrophic factor may be useful for the treatment of brain injuries, glaucoma, demyelinating diseases, and various neurodegenerative diseases that affect oligodendrocyte- myelinated CNS neurons.
  • ODNF may be used in therapies involving repair and regeneration of neurons after brain injury (e.g., evaluated as outlined in Example 12).
  • the central nervous system has little ability to repair itself.
  • the optic nerve or other myelinated tracts are injured in the CNS, the axons comprising these tracts are typically cut or damaged.
  • the neurons whose axons are damaged fail to regenerate the axons and die, causing permanent neurological disability.
  • the optic nerve such neuronal cell death results in blindness. Damage to axon tracts after spinal cord injury results in paralysis.
  • axotomized neurons die because they fail to get ODNF, and that delivery of exogenous ODNF to an injured brain region may be used to increase the percentage of injured neurons that survive and regenerate, thus alleviating some of the permanent neurological consequences (e.g., paralysis, blindness) that were heretofore inevitably associated with CNS injury.
  • ODNF may also be employed in the treatment of glaucoma, a disease associated with increased intraocular pressure.
  • glaucoma a disease associated with increased intraocular pressure.
  • One of the characteristics of glaucoma is the death of retinal ganglion cells. The reasons for such death are not fully understood.
  • the present invention contemplates that the retinal ganglion cells die because the elevated intraocular pressure blocks the retrograde transport of ODNF from the axons (where it is absorbed from oligodendrocytes) to the cell bodies, and accordingly, that intraocular application of ODNF may prevent retinal ganglion cell death caused by glaucoma.
  • oligodendrocytes die for unknown reason. Initially, new oligodendrocytes are generated, but as the disease progresses and more severe oligodendrocyte loss ensues, there is correspondingly less repair. It is known that sites of demyelination in multiple sclerosis are associated with axonal degeneration, suggesting that the neurons that used to project through the demyelinated region have died. The loss of such axons causes permanent paralysis because prior to the teachings herein, it has not been possible to stimulate the CNS to regenerate.
  • oligodendrocytes produce a potent neurotrophic factor may explain this axonal loss, since loss of oligodendrocytes would cause loss of their factor and ultimately death of the neurons that depend on this factor. Accordingly, it is contemplated that a primary problem in multiple sclerosis is not loss of oligodendrocytes, but loss of axons, and that delivery of exogenous ODNF into demyelinated brain regions may be employed to prevent such axonal loss, by preventing the death of the neurons that depended on oligodendrocytes for their survival.
  • Neurodegenerative diseases such as Alzheimer's disease and amyotrophic lateral sclerosis (ALS) may also be treated using ODNF.
  • ODNF amyotrophic lateral sclerosis
  • neurons typically die for unknown reason.
  • delivery of exogenous oligodendrocyte trophic factor into the affected regions of brains of patients with neurodegenerative disease may be employed to treat or delay the course of their disease.
  • the structure of the factor and/or information about biologically-active regions of the factor may be used to design peptide mimetics with increased stability, bioavailability and/or bioactivity relative to the native factor.
  • PBS Phosphate-buffered saline
  • Recombinant human insulin-like growth factor 1 IGF-1
  • basic fibroblast growth factor bFGF
  • transforming growth factor-alpha TGF- ⁇
  • TGF-S transforming growth factor- beta
  • IGF-1 insulin-like growth factor 1
  • bFGF basic fibroblast growth factor
  • TGF- ⁇ transforming growth factor-alpha
  • TGF-S transforming growth factor- beta
  • Insulin was obtained from Sigma Chemical Co. (St. Louis, MO).
  • Recombinant mouse neurotrophin-3 NT-3) was obtained from Yves Barde (Gotz, et al, 1992, Max Plank Institute for Psychiatry, Martinsried, Federal Republic of Germany), recombinant human brain-derived neurotrophic factor (BDNF) and neurotrophin-4/5 (NT-4/5) from Regeneron Pharmaceuticals, Inc.
  • CNTF rat ciliary neurotrophic factor
  • LIF human leukemia inhibitory factor
  • NT-3 may be obtained from Regeneron Pharmaceuticals
  • CNTF, LIF, IGF-1, IGF-2, bFGF and IL-6 may be obtained from Genzyme Diagnostics, Cambridge, MA
  • LIF, TGF- ⁇ , IGF-1, IGF-2, bFGF and IL-6 may be obtained from R&D Systems (Minneapolis, MN).
  • Retinas were removed from the eye in situ as follows. The animal was decapitated and skin overlying the eyes removed. The head was pinned to a block, and the anterior tissues of the eye were removed with a #11 scalpel blade while the cornea was held with a pair of rat-tooth, micro-dissecting forceps. The lens and vitreous humor were removed with forceps. The retina was then gently lifted away with a small spatula. Retinas were stored at room temperature in Eagle's Modified Essential Medium (MEM; Gibco/BRL Life Technologies, Gaithersburg, MD) until retinas were dissected from all animals.
  • MEM Eagle's Modified Essential Medium
  • Optic nerve and optic chiasm were dissected from postnatal day 8 (P8) S/D rats with micro-dissecting forceps and small scissors, collected in 35 mm petri dishes containing 2 ml of MEM supplemented with 10 mM Hepes (MEM/Hepes), and minced using small scissors.
  • the tectum was dissected with the aid of micro-dissecting forceps and a scalpel and temporarily stored in Hepes/MEM as above.
  • the neurocortex was dissected with the aid of micro-dissecting forceps and a scalpel and temporarily stored in Hepes/MEM as above.
  • a papain solution was prepared, immediately prior to the start of the dissection, by adding 150 units (retina, tectum and cortex) or 300 units (optic nerve) of papain (Worthington Biochemical, Freehold, NJ) to 10 ml of Earle's Balanced Salt Solution (EBSS; Gibco/BRL Life Technologies, Gaithersburg, MD) in a 15 ml blue-top conical centrifuge tube, and placing the mixture in a 37 °C water bath to dissolve the papain.
  • EBSS Earle's Balanced Salt Solution
  • One hundred microliters of a 4 mg/ml DNAse (0.004%, Worthington Biochemical Co ⁇ ., Freehold, NJ) solution were added to the MEM/papain mixture after the papain had dissolved.
  • the solution was mixed with 2.4 mg of L-cysteine, adjusted to a pH of about 7.4 with 1M NaOH, and passed through a 0.22 micron filter into sterilized scintillation vials.
  • the MEM bathing the tissue was removed with a sterile pasteur pipette and replaced with 2 ml of the papain solution.
  • the tissue was then decanted to a scintillation vial containing fresh papain solution, and the vial was placed in a 37° C water bath for 30 minutes with gently swirling approximately every 10 minutes.
  • the tissue and papain solution in the scintillation vial were then decanted to a 15 ml blue-top centrifuge tube. After the tissue settled to the bottom, the old papain solution was removed with a sterile pipet and the tissue was gently rinsed with 3 ml of ovomucoid inhibitor solution, which contained ovomucoid (15 mg; Boehringer-Mannheim) and BSA (10 mg; Sigma catalog no. A-7638) dissolved in MEM (GIBCO/BRL). The solution was adjusted to pH 7.4 and sterilized with a 0.22 ⁇ m filter). The pieces of tissue were allowed to settle, and the rinse solution removed.
  • Retinal, tectal and cortical tissue was then triturated sequentially with a 1 ml plastic pipette tip (Rainin Instr. Co., Woburn, MA), while optic nerve tissue was triturated with #21 and then #23 gauge needles.
  • the following steps were repeated 6-10 times (until the tissue was completely broken up): (i) one ml of ovomucoid solution was added and the tissue was gently pulled up into the pipet and expelled, (ii) the dissociate was allowed to settle by gravity for about 30 seconds, and (iii) the supernatant was collected.
  • the final cell suspension comprised of the supematants from the 6-10 trituration cycles, contained about 20 million cells per P8 retina, about 50,000 cells per P8 optic nerve, about 10 6 cells per P0 tectum, and about 10 7 cells per P8 cortex.
  • the cell suspension was then spun at 800 Xg for 10 minutes in a 15 ml blue-top centrifuge tube to separate the cells from the ovomucoid solution.
  • the supematant was discarded and cells resuspended in 1 ml of MEM.
  • the cell suspension was then gently layered onto 6 ml of an MEM solution containing 60 mg of ovomucoid and 60 mg of BSA (pH adjusted to pH 7.4) and spun again at 800 Xg for 10 minutes in a 15 ml blue-top centrifuge tube. The supernatant was discarded and the cells were resuspended in 12 ml of Eagle's Minimum Essential Medium (MEM) solution containing BSA (0.1 %).
  • MEM Eagle's Minimum Essential Medium
  • Retinal ganglion cells were purified from the retinas and optic nerves of E18 or P8 rats using a panning procedure (Barres, et al., 1988; Barres and Chun, 1993). A brief description of the procedure follows.
  • 100 mm x 15 mm or 150 mm x 15 mm petri dishes were prepared as described below. Dishes made of tissue culture plastic were not used due to potential problems with non-specific cell sticking. None of the incubation solutions used to coat panning plates were sterilized with 0.22 ⁇ m filters, since much of the protein would have been lost in the filter.
  • Panning plates comprising the first set were incubated with 5 ml of 50 mM Tris buffer (pH 9.5) containing 0.5 ⁇ g/ml affinity-purified goat anti-rabbit IgG (H + L; Accurate Chemical & Scientific Co ⁇ ., Westbury, NY) for 12 hours at 4°C The supernatant was removed and the dishes were washed three times with 8 ml of PBS. To prevent nonspecific binding of cells to the panning dish, 5 to 15 ml of Eagle's MEM with BSA (0.2%) was placed on each dish for at least 20 minutes, and this solution remained on the dish until it was used.
  • Tris buffer contained 5 ⁇ g/ml affinity-purified goat anti-mouse IgM (mu-chain specific; Accurate
  • the dishes were then washed as above and incubated with 5 ml of a supernatant from mouse monoclonal cell line Tl lD7e2, containing IgM antibodies against Thy 1.1, for at least one hour at room temperature. The supernatant was removed and the plate washed three times with PBS. In order to prevent nonspecific binding of cells to the panning dish, 5 ml of Minimal Essential Medium (MEM; Gibco/BRL) with 2 mg/ml BSA was placed on the plate for at least 20 minutes.
  • MEM Minimal Essential Medium
  • Tl lD7e2 is available from the American Type Culture Collection (ATCC; Rockville, MD; Accession number TIB 103).
  • FIG. 1A A retinal cell suspension (20) prepared as above and containing retinal ganglion cells (22), macrophages (24) and various other cells, including Thyl negative cells (26), was incubated with antiserum containing rabbit-anti-rat- macrophage antibodies (28; Accurate Chemical & Scientific Co ⁇ ., 1:100) for 20 minutes (Fig. 1A), centrifuged at 800 Xg for 10 minutes, resuspended in MEM, and incubated on a goat-anti-rabbit IgG (30) (first set) panning plate (32; 150 mm) at room temperature for 45 minutes (Fig. IB).
  • the plate was gently swirled after 20 minutes to ensure access of all cells to the surface of the plate. If cells from more than 8 retinas were panned, the nonadherent cells were transferred to another (first set) 150-mm anti-rabbit IgG panning plate for an additional 30 minutes.
  • Non-adherent cells were removed with the suspension, filtered through a UV- sterilized 15 micron Nitex mesh (Tetko, Elmsford, NY) to remove small clumps of cells, placed on a second set panning plate (34) derivatized with goat-anti-mouse IgM (36) and mouse anti-Thy-1 (38; T11D7), and incubated on the plate (Fig. IC) as described above. After 1 hour, the plate was washed eight times with 6 ml of PBS and swirled moderately vigorously to dislodge nonadherent cells (Fig. ID).
  • Oligodendrocytes and Astrocytes Purification of O-2A Progenitor Cells. Oligodendrocytes and Astrocytes. Oligodendrocytes and their precursors were purified from the optic nerves of P8 S/D rats as previously described (Barres, et al. , 1992; Barres, 1993).
  • Panning Plates Three sets of panning plates were prepared. The first set was incubated with affinity-purified goat anti-mouse IgG (H+L chain specific, Accurate Chemical & Scientific Co ⁇ ., Westbury, NY) as above, washed as above, and further incubated with anti-RAN-2 IgG monoclonal antibody (supematant 1 :4; Bartlett, et al., 1981) as above.
  • RAN-2 is an unknown protein that is specifically expressed on optic nerve type-1 astrocytes (Bartlett, et al., 1981).
  • the second and third sets of panning plates were both incubated with affinity- purified goat anti-mouse IgM (mu-chain specific, Accurate), as above, washed, and further incubated with either anti-GC (anti-galactocerebroside glycolipid) monoclonal IgG antibody (RMab supernatant 1:4; Ranscht, et al., 1982; second set) or with anti-A2B5 monoclonal IgM ascites at 1:2000 (Eisenbarth, et al., 1979; third set).
  • affinity- purified goat anti-mouse IgM mo-chain specific, Accurate
  • A2B5 is a ganglioside specif cally expressed on oligodendrocyte precursor cells, while £alactocerebroside glycolipid is specifically expressed on oligodendrocytes.
  • the antibodies were diluted in Hepes-buffered Minimal Eagle's Medium (MEM/Hepes, Gibco/BRL) containing bovine serum albumin (BSA, lmg/ml; Sigma A4161), in order to block the non-specific adherence of cells to the panning plates. The antibody solution was removed, the plates washed three times with PBS, and PBS left on the plates until use.
  • MEM/Hepes Hepes-buffered Minimal Eagle's Medium
  • BSA bovine serum albumin
  • the optic nerve cell suspension was resuspended in 7 ml of L15 Air Medium (Gibco/BRL), containing insulin (5 ⁇ g/ml; Sigma Chemical) and filtered through UV-sterilized Nitex mesh (15 ⁇ m pore size, Tetko).
  • the cell suspension was placed on a RAN-2 (first set) plate for 30 minutes at room temperature, with brief and gentle agitation after 15 minutes, to deplete type-1 astrocytes, meningeal cells, microglia and macrophages.
  • the non-adherent cells were transferred to a second RAN-2 plate for 30 minutes, after which the non-adherent cells were transferred to a (second set) GC plate for 45 minutes to deplete oligodendrocytes.
  • the second and third set plates containing adherent GC + oligodendrocytes and A2B5 + O-2A progenitors, respectively, were washed 8 times with 6 ml of PBS or MEM/Hepes with moderately vigorous agitation to remove all antigen-negative non- adherent cells. The progress of nonadherent cell removal was monitored under an inverted phase-contrast microscope, and washing was terminated when only adherent cells remained.
  • Optic nerves were dissected from P2 rats.
  • the first panning dish was coated with the MRC-OX7 Thy 1.1 antibody (IgG; Serotec Ltd., Station Approach, UK) to deplete the suspension of meningeal fibroblasts
  • the second dish was coated with A2B5 and GC antibodies (as above) to deplete the suspension of O-2A lineage cells
  • the final dish was coated with the C5 monoclonal antibody (Miller, et al. , 1984) directed against an unknown antigen on neuroepithelial cells to select any remaining neuroepithelial cells, which were greater than 99.5% GFAP-positive type-1 astrocytes.
  • the astrocytes were released from the C5 plate using a trypsin solution as described above.
  • Glutamatergic cortical projection neurons were purified from the neurocortex of P8 rats following the protocol for retinal ganglion cell purification described above.
  • RRCs retinal ganglion cells
  • Falcon retinal ganglion cells
  • merosin 2 ⁇ g/ml
  • Telios Pharmaceuticals Inc. San Diego, CA, available from Gibco/BRL
  • MTT modified Bottenstein-Sato
  • All values were normalized to the percentage of surviving cells at 3 hours after plating, which represented the percentage of cells that survived the purification procedure. This initial viability was typically about 85%.
  • the MBS medium was similar to Bottenstein-Sato (B-S) medium (Bottenstein and Sato, 1979), but used "NEUROBASAL” (Gibco/BRL), instead of Dulbecco's Modified Eagle's Medium (DMEM), as the base.
  • NEUROBASAL is a recently-described basal medium that has been optimized for neuronal cell culture (Brewer, et al., 1993). Media employing "NEUROBASAL” promoted better survival of RGCs than those employing DMEM, and differed from those using DMEM primarily in that they had a lower osmolarity (235 mOsm for "NEUROBASAL” vs. 335 mOsm for DMEM). The final osmolarity of the MBS "NEUROBASAL "-based culture medium used in the present experiments, after addition of the serum-free additives, was about 260 mOsm.
  • the serum-free components added to the "NEUROBASAL" base to make MBS medium were bovine serum albumin (BSA), selenium, putrescine, thyroxine, tri- iodothyronine, transferrin, progesterone, pyruvate and glutamine.
  • BSA bovine serum albumin
  • putrescine putrescine
  • thyroxine tri- iodothyronine
  • transferrin tri- iodothyronine
  • transferrin transferrin
  • progesterone progesterone
  • pyruvate glutamine
  • glutamine Various trophic factors and other additives were added as indicated in individual experiments.
  • the MBS medium was prepared with a highly purified, crystalline grade of BSA (Sigma, A4161), in order to avoid contaminating survival factors.
  • the component concentrations of the MBS medium used in the present experiments are provided in Table 1, below.
  • BSA bovine serum albumin
  • progesterone 60 ng/ml pyruvate 1 mM glutamine 1 mM
  • Co-culture experiments were performed to assess the effects of soluble factors released by retinal cells, tectal cells, optic nerve cells, and purified astrocytes or oligodendrocytes on RGC survival.
  • Approximately 50,000 cells were plated onto the bottom of poly-d-lysine or merosin-coated wells in a 24-well plate. The cells were incubated at 37°C under a 10% CO 2 atmosphere for at least three days to condition serum- free Sato medium, which, depending on the experiment, may have contained additional trophic factors (indicated). In some cases (indicated), purified oligodendrocytes were allowed to mature for 10 days prior to further use.
  • MTT survival assay was performed as described by Mosmann (1983). MTT
  • Glial cell types were identified by their characteristic antigenic phenotypes: astrocytes were labeled by anti-GFAP antiserum, oligodendrocyte precursor cells by A2B5 antibody and oligodendrocytes by anti-GC antibody (Ranscht, et al, 1982). M. Electrophvsiological Recording
  • IGF-1 insulin-like growth factor 1
  • BDNF brain-derived neurotrophic factor
  • NT-4/5 neurotrophin-4/5
  • CNTF ciliary neurotrophic factor
  • LIF leukemia inhibitory factor
  • bFGF basic fibroblast growth factor
  • TGF- ⁇ transforming growth factor-alpha
  • IGF-1 IGF-1
  • IGF-2 insulin at concentrations sufficiently high to activate IGF-1 receptors (5 ⁇ g/ml; Sara and Hall, 1990), as well as BDNF, NT-4/5, CNTF, LIF, IL-6, bFGF, and TGF- ⁇ .
  • Trophic factors which at high concentration (50 ng/ml) did not promote the survival of RGCs in the presence of forskolin included NT-3, nerve growth factor (NGF), transforming growth factors beta 1, 2, and 3, glial cell-derived neurotrophic factor (GDNF), glial growth factor (GGF), interleukin-3 (IL-3) and interleukin-7 (IL-7).
  • NGF nerve growth factor
  • GDNF transforming growth factors beta 1, 2, and 3
  • GDNF glial cell-derived neurotrophic factor
  • GGF glial growth factor
  • IL-7 interleukin-7
  • the survival promoting effects of different concentrations of BDNF and CNTF on purified RGCs were determined using dose-response curves in medium containing forskolin (5 ⁇ M) and insulin (5 ⁇ g/ml).
  • Figure 2A shows dose-response curves for BDNF and CNTF.
  • the BDNF concentration that promoted half-maximal survival was about 2 ng/ml and for CNTF was about 200 pg/ml, similar to the values reported for their survival promoting effects on rodent peripheral neurons (Hughes, et al., 1993; Arakawa, et al., 1990).
  • the factors were grouped into three classes: (i) insulin-like growth factors (e.g., insulin, IGF-1, IGF-2), (ii) neurotrophins (e.g., BDNF and NT-4/5), and (iii) CNTF-like cytokines (e.g., CNTF, LIF, and IL-6). Combinations of two or three factors from within a class did not give a significantly better survival than the individual factors alone. In contrast, a combination of factors from different classes produced additive effects on survival.
  • insulin-like growth factors e.g., insulin, IGF-1, IGF-2
  • neurotrophins e.g., BDNF and NT-4/5
  • CNTF-like cytokines e.g., CNTF, LIF, and IL-6
  • FIG. 2B shows the effects of combining survival factors on short term (3 day) retinal ganglion cell survival. All factors were used at plateau concentrations. Insulin plus BDNF, for example, was better than insulin or BDNF alone, while insulin plus BDNF and CNTF was better than any two of these alone. The majority of the cells could be saved, at least for 3 days, by the combination of forskolin, insulin, BDNF, CNTF and growth on a merosin-coated surface. The addition of bFGF and TGF- ⁇ did not promote a further increase in survival, but additive effects were observed when these factors were combined with CNTF.
  • Example IB The experiments described in Example IB, above, were carried out over 28 days to determine whether long-term survival of RGCs could be promoted by combinations of peptide trophic factors and cAMP elevating agents.
  • the medium also contained forskolin (5 ⁇ M) and insulin (5 ⁇ g/ml).
  • Exemplary results are shown in Figure 3.
  • the majority of cells had died when cultured in only one or two factors, for instance BDNF and insulin.
  • the cells that survived for one week were able to survive for at least 1 month.
  • the majority of cells cultured in either BDNF and insulin or in CNTF and insulin had died, strongly suggesting that BDNF and CNTF do not promote the survival of different subsets of cells, but act synergistically on individual cells to promote long-term survival.
  • Figs 4 A and 4B Exemplary results are shown in Figs 4 A (3 day culture) and 4B (7 day culture).
  • Fig. 4A the cells were cultured either at high density (50,000 cells/well), low density
  • the effects of visual pathway glia on survival of RGC cells was determined using conditioning layers of glial cells.
  • Purified P8 RGCs were cultured over a conditioning layer of highly purified postnatal optic nerve astrocytes (purified to greater than 99.5% purity by sequential immunopanning; see Materials and Methods). Cell survival was measured after 3 days using the MTT assay. The results are summarized in Table 3, below. In serum-free MBS medium containing only forskolin and insulin but no BDNF or CNTF, the astrocytes weakly promoted RGC survival. In the presence of BDNF and CNTF, however, there was little further additive effect.
  • oligodendrocytes promote RGC survival.
  • purified P8 RGCs were cultured as above over a conditioning layer of immature or mature oligodendrocytes.
  • Immature oligodendrocytes were oligodendrocyte precursor cells that were purified to greater than 99.95% purity by sequential immunopanning from P8 optic nerve as described above and in Barres, et al., 1992.
  • Mature oligodendrocytes were prepared by aging the immature oligodendrocytes for 10 days.
  • FIGS 5A and 5B show exemplary photomicrographs of purified P8 retinal ganglion cells cultured for 14 days in the absence (Fig. 5A) or presence (Fig. 5B) of a conditioning layer of mature oligodendrocytes.
  • the cells were cultured in serum-free MBS medium containing plateau concentrations of BDNF, CNTF and IGF-1 on merosin-coated glass coverslips.
  • Most of the retinal ganglion cells grown under the conditions shown in Fig. 5 A died by two weeks in culture. In contrast, the majority of cells grown over the oligodendrocytes extended processes and survived for at least four weeks.
  • El 8 RGCs were purified and cultured in MBS serum-free medium containing various peptide trophic factors as described above.
  • the survival of purified El 8 retinal ganglion cells cultured in serum-free MBS medium containing high insulin (5 ⁇ g/ml) and various survival factors (50 ⁇ g/ml; used as indicated) assessed after 3 days of culture by the MTT assay is shown in Figure 6.
  • BDNF as well as NT-4/5 significantly promoted the survival of the embryonic cells if forskolin was present in the medium.
  • the survival of the purified El 8 retinal ganglion cells was assessed using the MTT assay after 3 days of culture above a conditioning layer of various cell types in serum-free MBS medium containing forskolin (5 ⁇ M) and plateau levels of BDNF, CNTF, and insulin.
  • the conditioning retinal, optic nerve and tectal cells were isolated from El 8 rats, whereas the oligodendrocytes were isolated from P8 rats and matured for 10 days prior to the assay.
  • Figs. 8 A and 8B The mo ⁇ hology of purified El 8 retinal ganglion cells cultured in serum-free MBS medium containing plateau concentrations of BDNF, CNTF, IGF-1 on merosin-coated wells in a 96-well plate is shown in Figs. 8 A and 8B.
  • the medium bathing the cells in Fig. 8A contained only the aforementioned components, while the medium bathing the cells in Fig. 8B also contained conditioned medium from El 8 tectal cells (in a 1: 1 ratio). Most of the cells grown under the conditions shown in Fig. 8A died by three days of culture. The majority of cells grown with tectal conditioned medium, however, extended processes and survived for at least 3 days (the longest time point assayed; Fig. 8B. EXAMPLE 6
  • Purified P8 retinal ganglion cells were cultured in serum-free MBS medium for 3 days in the indicated survival factors. In some cases, either forskolin (5 ⁇ M) or potassium chloride (10 or 50 mM as indicated; when not indicated, the results for 10 and 50 mM were not significantly different) was also included in the medium.
  • TTX tetrodotoxin
  • KYN a blocker of ionotropic glutamate receptors
  • Results shown in Figure 9B, show that neither tetrodotoxin nor kynurenic acid blocked the ability of forskolin to facilitate BDNF and CNTF promoted survival, strongly suggesting that cAMP is the distal effector of electrical activity with respect to its effects on trophic factor-mediated survival.
  • the protein kinase A inhibitor, Rp-cAMP was used to determine whether the effects of forskolin were due to the activation (stimulation) of a cAMP-dependent protein kinase in the cells.
  • the enhancement of survival induced either by forskolin or depolarization was completely blocked by 100 ⁇ M Rp-cAMP.
  • Rp-cAMP brought the survival level down to the level seen with BDNF alone (the basal survival in the absence of forskolin).
  • Sp-cAMP 100 ⁇ M (an isomer of Rp-cAMP that mimics the effect of forskolin) was tested as a control, and resulted in survival levels similar to those observed with forskolin.
  • NMDA glutamate receptor agonists
  • kainate 100 ⁇ M
  • quisqualate 100 ⁇ M
  • a combination of NMDA and kainate resulted in survival levels almost as high as those facilitated by forskolin.
  • quisqualate was added along with NMDA and kainate, the survival mimicked the effect of forskolin.
  • the survival effects of the glutamate receptor agonists were also blocked by Rp-cAMP.
  • NMDA, kainate or quisqualate applied individually were less effective. Even at 100 times higher concentrations of NMDA and kainate, no evidence of excitotoxicity (Choi, 1994) was observed after 3 days of culture.
  • the electrical properties of the cultured RGCs were measured as described in Materials and Methods, above, to assess the physiological state of the cells.
  • Purified retinal ganglion cells in the serum-free culture conditions described above fire action potentials in response to depolarizing current injection (Fig. 12A) and exhibit spontaneous excitatory postsynaptic currents (Fig. 12B).
  • Thy-1 positive cerebral cortical neurons were purified by immunopanning from postnatal day 8 rat cerebral cortices as described above. The cells were plated in
  • Serum-free MBS medium containing CNTF (50 ng/ml) and high insulin (5 ⁇ g/ml) was conditioned by a dense culture of mature oligodendrocytes for at least three days.
  • non-CNTF, non-insulin survival activity was a protein
  • a sample of the conditioned medium was heat inactivated by boiling for 5 minutes.
  • Another sample of the medium (1 ml) was incubated for 16 hours at
  • the oligodendrocyte conditioned medium was centrifuged through a "CENTRIPREP- 10" concentrator membrane (Amicon, Beverly, MA), which excludes molecules greater than 10 kD, at 2500 g for 50 min. This manipulation resulted in a 10-fold concentration of the medium components > 10 kD. The ability of a 20-fold dilution of the concentrated medium (containing activities greater than 10 kD) and a
  • the medium was then diluted 1:1 with the indicated oligodendrocyte conditioned medium that had been treated as indicated. The cells were incubated in this medium for 5 days.
  • oligodendrocyte-derived neurotrophic factor is a trypsin-sensitive heat-sensitive > 10 kD proteinaceous factor secreted by oligodendrocytes into the bathing medium.
  • a cDNA library was prepared from highly purified (> 99.95% pure) mature oligodendrocytes in the expression vector pMET7 (Takabe, 1988), which contains the SR alpha promoter, the T7 polymerase binding site 5' to a polylinker modified for No ⁇ ISaH directional insertion of cDNA, and the SV40 late-gene splice junction.
  • the SR alpha promoter contained in the vector is up to 100 times more efficient in driving the expression of exogenously introduced genes compared to unmodified SV40 early promoter constructs (Kriegler, 1990).
  • the cDNA fragments were ligated to Sail linkers, digested with Notl and size selected over a "SEPHACRYL” S-500 column (Promega Co ⁇ ., Madison, Wl; "SEPHACRYL” is a suspension of particles of crosslinked co-polymer of allyl dextran and ⁇ , ⁇ '-methylenebisacrylamide in —20% ethanol). Fragments greater than 1 kb were directionally ligated into NotI and Sail sites in the pMET7 vector, and the library was electroporated into electrocompetent DH12S cells (Gibco/BRL).
  • a characterization of the library revealed over one million independent recombinants with an average insert size 1.6 kB. Two of 8 clones analyzed had insert sizes of over 3.0 kB.
  • the library was amplified and divided into pools, from which groups of plasmids were isolated for transfection using lipofectamine (or DEAE Dextran) into
  • conditioned medium from the transfected cells is collected and assayed for survival-promoting activity (as described above) on purified postnatal RGCs.
  • Conditioned medium from untransfected COS7 cells is tested to verify that the COS7 cells do not produce any factors that enhance survival of purified RGCs. Pools of cells that enhance survival are then subcioned and rescreened until individual clones having survival activity are identified.
  • Northem blot and in situ hybridization analyses are performed to verify that the mRNAs are expressed specifically by oligodendrocytes but not astrocytes.
  • a clone encoding the full-length ODNF is used to prepare a fusion protein for the production of recombinant survival factor polypeptide.
  • the coding sequences are cloned into an expression plasmid, such as pGEX, to produce corresponding polypeptides.
  • the recombinant pGEX plasmid is transformed into an appropriate strains of E. coli and fusion protein production is induced by the addition of IPTG
  • Solubilized recombinant fusion protein is then purified from cell lysates of the induced cultures using glutathione agarose affinity chromatography according to standard methods (Ausubel, et al.).
  • the rat optic nerve is surgically cut or crushed retroorbitally while the rat is under inhalation anesthesia as previously described (Berkelaar, et al., 1994). This procedure avoids injury to major retinal blood vessels and enables assessment of the amount of regrowth of neurofilament-positive axons into the optic nerve. The amount of regeneration is measured by removing the optic nerves after a regeneration period of two weeks following P8 optic nerve transection. P8 animals are used in the initial studies because previous experiments have established that it is possible to successfully deliver high levels of trophic factors into the optic nerves and retina at this age (see below). The experiments are then extended to include older rats. One group of animals is treated with intraocular injections of ODNF, anther group with intracerebral injections, and control groups of animals receive sham injections.
  • the amount of regeneration is assessed by sectioning and labeling with neurofilament antibodies.
  • a quantitative assessment of the amount of regeneration is obtained by cutting the optic nerves into three pieces (retinal, middle, and chiasmal), using an immunoenzyme assay to measure the total content of neurofilament protein, and comparing this to control untransected nerves.
  • Stably-transfected cell lines secreting RGC survival factors are transplanted into the subarachnoid space of P8 rats as previously described (Barres, et al., 1992, 1993, 1993a, 1994; Barres and Raff, 1993).
  • the optic nerves of 4 "test” groups of animals are transected or crushed, while those of 4 "control” groups are left intact.
  • the animals are maintained for 10 days following nerve transection and are then sacrificed using halothane anesthesia.
  • the optic nerves from each of the 4 control and test groups are fixed in 4% paraformaldehyde, cryosectioned and stained with neurofilament antibodies to assess whether regeneration has occurred.
  • the factor-secreting cell lines that are used include 293 cells that secrete human BDNF (homologous to rat BDNF) and 293 cells that release a secretable form of rat CNTF, that has been engineered to contain the secretory signal sequence of human growth factor.
  • Stably transfected 293 cells containing recombinant ODNF are also prepared and used to assess the effects of this factor on RGC survival. Combinations of recombinant factors are also evaluated as describe above. The levels of trophic factor delivered into the optic nerve are assessed by enzyme-linked immunesorbent assay (ELISA). The optic nerve is removed from the meningeal sleeve for this analysis.
  • ELISA enzyme-linked immunesorbent assay
  • the experiment described above are conducted both in the presence and absence of intraocular injection of forskolin, to evaluate the in vivo effectiveness of the drug.
  • the injections are repeated every 4 days throughout the postoperative regeneration period.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une culture in vitro de cellules neuronales du système nerveux central, caractérisée par l'absence de cellules nourricières ou de milieu conditionné par des cellules nourricières, un milieu de culture pratiquement sans sérum et une viabilité étendue. L'invention concerne également des procédés de culture de cellules du système nerveux central purifiées dans des conditions définies, sur des périodes étendues, ainsi que des procédés permettant de favoriser in vivo la régénération et la survie de neurones endommagés du système nerveux central.
PCT/US1996/008079 1995-06-02 1996-05-30 Survie et regeneration de longue duree de neurones du systeme nerveux central WO1996038541A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU60267/96A AU6026796A (en) 1995-06-02 1996-05-30 Long-term survival and regeneration of central nervous syste ms neurons

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US45832395A 1995-06-02 1995-06-02
US45840895A 1995-06-02 1995-06-02
US08/458,323 1995-06-02
US08/458,408 1995-06-02

Publications (1)

Publication Number Publication Date
WO1996038541A1 true WO1996038541A1 (fr) 1996-12-05

Family

ID=27038955

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1996/008079 WO1996038541A1 (fr) 1995-06-02 1996-05-30 Survie et regeneration de longue duree de neurones du systeme nerveux central

Country Status (2)

Country Link
AU (1) AU6026796A (fr)
WO (1) WO1996038541A1 (fr)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245564B1 (en) 1997-01-23 2001-06-12 Cornell Research Foundation, Inc. Method for separating cells
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US7150989B2 (en) 2001-08-10 2006-12-19 Cornell Research Foundation, Inc. Telomerase immortalized neural progenitor cells
US7468277B2 (en) 1999-12-23 2008-12-23 Cornell Research Foundation, Inc. Enriched preparation of human fetal multipotential neural stem cells
US7576065B2 (en) 2002-02-15 2009-08-18 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US8039591B2 (en) 2008-04-23 2011-10-18 Codman & Shurtleff, Inc. Flowable collagen material for dural closure
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
US8795710B2 (en) 2004-02-09 2014-08-05 Codman & Shurtleff, Inc. Collagen device and method of preparing the same

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245564B1 (en) 1997-01-23 2001-06-12 Cornell Research Foundation, Inc. Method for separating cells
US6692957B2 (en) 1997-01-23 2004-02-17 Cornell Research Foundation, Inc. Method for separating cells
US8263402B1 (en) 1998-10-19 2012-09-11 Cornell Research Foundation, Inc. Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
US7468277B2 (en) 1999-12-23 2008-12-23 Cornell Research Foundation, Inc. Enriched preparation of human fetal multipotential neural stem cells
US7037493B2 (en) 2000-05-01 2006-05-02 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US7803752B2 (en) 2000-05-01 2010-09-28 Cornell Research Foundation, Inc. Method of inducing neuronal production in the caudate nucleus and putamen
US7807145B2 (en) 2000-05-01 2010-10-05 Cornell Research Foundation, Inc. Method of inducing neuronal production in the brain and spinal cord
US7150989B2 (en) 2001-08-10 2006-12-19 Cornell Research Foundation, Inc. Telomerase immortalized neural progenitor cells
US7576065B2 (en) 2002-02-15 2009-08-18 Cornell Research Foundation, Inc. Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US8795710B2 (en) 2004-02-09 2014-08-05 Codman & Shurtleff, Inc. Collagen device and method of preparing the same
US8039591B2 (en) 2008-04-23 2011-10-18 Codman & Shurtleff, Inc. Flowable collagen material for dural closure

Also Published As

Publication number Publication date
AU6026796A (en) 1996-12-18

Similar Documents

Publication Publication Date Title
Martinou et al. Cholinergic differentiation factor (CDF/LIF) promotes survival of isolated rat embryonic motoneurons in vitro
Kleitman et al. Schwann cell surfaces but not extracellular matrix organized by Schwann cells support neurite outgrowth from embryonic rat retina
Delree et al. Purification and culture of adult rat dorsal root ganglia neurons
AU713384B2 (en) Methods of treating disorders of the eye
WO1999029279A2 (fr) Survie a long terme et regeneration de neurones du systeme nerveux central
Meyer-Franke et al. Astrocytes induce oligodendrocyte processes to align with and adhere to axons
AU707599B2 (en) Use of neuregulins as modulators of cellular communication
Raabe et al. Cultured neonatal Schwann cells contain and secrete neuregulins
DE69635924T2 (de) Isolierung und züchtung von schwannzellen
US6033660A (en) Method of treating a nervous system injury with cultured schwann cells
RU2157223C2 (ru) Трофические факторы для регенерации центральной нервной системы
WO1996030403A9 (fr) Procedes de traitement de troubles oculaires
Wei et al. Survival, synaptogenesis, and regeneration of adult mouse spiral ganglion neurons in vitro
WO1997007200A1 (fr) Compositions cellulaires precurseurs d'oligodendrocytes adultes et procedes
WO1997007200A9 (fr) Compositions cellulaires precurseurs d'oligodendrocytes adultes et procedes
US6214334B1 (en) Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
Guettier-Sigrist et al. Cell types required to efficiently innervate human muscle cells in vitro
WO1996038541A1 (fr) Survie et regeneration de longue duree de neurones du systeme nerveux central
Muir et al. Rat sciatic nerve Schwann cell microcultures: responses to mitogens and production of trophic and neurite-promoting factors
AU727037B2 (en) Methods of treating disorders of non-visual sensory epithelia
Kuffler et al. Neutrophic influence of denervated sciatic nerve of on adult dorsal root ganglion neurons
MXPA01004544A (es) Metodo para mejorar la proliferacion de las celulas pilosas del oido interno utilizando ligandos para los receptores her2 y/o her3.
McLoon et al. Schwann cell-conditioned medium promotes neurite outgrowth from explants of fetal rat retina and tectum in vitro
Copray et al. Survival and neurite formation of mesencephalic trigeminal neurones of the rat in vitro
Shao et al. 7S nerve growth factor has different biological activity from 2.5 S nerve growth factor in vitro

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA